Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Betta Pharmaceuticals Partners with Westlake University on Pharma Innovation

Fineline Cube Jan 8, 2026
Company Deals

Viva Biotech and CMS Forge AI-Powered Drug Development Alliance

Fineline Cube Jan 8, 2026
Company Deals

Hisun and ECNU Forge AI Drug Discovery Partnership

Fineline Cube Jan 8, 2026
Company Deals Drug

Sciclon Licenses Augtyro Promotion Rights from Zai Lab for China Market

Fineline Cube Jan 8, 2026
Company Deals Drug

Pfizer Partners with Cartography on $850 Million Tumor Antigen Discovery Deal

Fineline Cube Jan 8, 2026
Policy / Regulatory

NMPA Issues Priority Review Guidelines for Clinically Urgent Overseas Drugs

Fineline Cube Jan 8, 2026
Company Deals Drug

Sciclon Licenses Augtyro Promotion Rights from Zai Lab for China Market

Fineline Cube Jan 8, 2026
Company Drug

Hengrui’s Retlirafusp α Wins NMPA Approval for First-Line Gastric Cancer

Fineline Cube Jan 8, 2026
Company Deals

Zhaoke Ophthalmology Indonesia Distribution Deal – BRIMOCHOL PF Eyes on Market Expansion

Fineline Cube Nov 8, 2025

China‑listed Zhaoke Ophthalmology Ltd. (HKG: 6622) announced a new distribution and supply agreement with Indonesia’s...

Company Deals

Shanghai‑Boehringer Ingelheim MOU Launches Stroke Prevention Initiative – Strengthening China Health 2030

Fineline Cube Nov 8, 2025

During the 8th China International Import Expo (CIIE), the Shanghai Medical Association (SMA) and Boehringer Ingelheim...

Company Deals Hospital

Boehringer Ingelheim Taps Beijing Friendship Hospital for MASH Trials – Expands China Key Initiative

Fineline Cube Nov 8, 2025

Boehringer Ingelheim announced at the 8th China International Import Expo (CIIE) that it has signed...

Company

Zai Lab Q3 2025 Revenue Up 13% YoY to $115.4 M, Led by Nuzyra and Xacduo; Zejula Slows

Fineline Cube Nov 8, 2025

Zai Lab Limited (NASDAQ: ZLAB, HKG: 9688) released its third‑quarter 2025 financial results, reporting total...

Company Deals

Eisai China Partners with Shanghai Pharmaceuticals Holding – Focus on Oncology, Neuroscience and Sleep Disorders

Fineline Cube Nov 8, 2025

In a high‑profile signing at the 8th China International Import Expo (CIIE), Eisai China (TYO:...

Policy / Regulatory

NHSA Pilot AI Review Accelerates Full‑Process Medical Insurance Assessment in 7 Chinese Provinces

Fineline Cube Nov 8, 2025

The National Healthcare Security Administration (NHSA) has announced a three‑phase, AI‑powered review pilot covering Beijing,...

Policy / Regulatory

US FDA’s CNPV Fast‑Track Program Expands to 15 Drugs, Cutting Review Time to Months

Fineline Cube Nov 8, 2025

The Commissioner’s National Priority Voucher (CNPV) pilot has just added 15 therapies to its two‑batch...

Company Deals

Sichuan Biokin Launches on HKEX, Raises HK$3.3 B in $389/Share Offering – A Milestone for China’s Biotech

Fineline Cube Nov 8, 2025

China’s Sichuan Biokin Pharmaceutical Co., Ltd. (SHA: 688506) announced its successful initial public offering (IPO)...

Medical Device

LifeTech Scientific Secures NMPA Approval for G‑Branch TAAA Stent‑Graft System

Fineline Cube Nov 8, 2025

LifeTech Scientific Corporation (HKG: 1302) announced that China’s National Medical Products Administration (NMPA) has granted...

Company

Viatris Posts Q3 2025 Revenue Dip, Highlights Emerging‑Market Branded Growth and Aculys Pharma Acquisition

Fineline Cube Nov 8, 2025

U.S.‑based Viatris Inc. (NASDAQ: VTRS) released its third‑quarter 2025 earnings, showing a 2 % year‑over‑year (YOY)...

Company Drug

Humanwell Healthcare Secures NMPA Approval to Launch First Fixed‑Dose Combination for Pulmonary Arterial Hypertension

Fineline Cube Nov 8, 2025

Humanwell Healthcare (Group) Co., Ltd (SHA: 600079) announced that its investigational compound HWH217 has received...

Company Drug

Eli Lilly & Novo Nordisk Reach U.S. Deal to Cut Obesity‑Drug Prices, Unlock Medicare & Medicaid Access

Fineline Cube Nov 8, 2025

Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO) announced a historic agreement with the...

Medical Device

Johnson & Johnson Launches ETHICON 4000 3D Laparoscopic Stapler in China

Fineline Cube Nov 8, 2025

Johnson & Johnson (J&J, NYSE: JNJ) announced today the commercial rollout of its ETHICON 4000 laparoscopic stapler...

Company

BeOne Medicines Posts $1.4 B Q3 2025 Revenue, Driven by BRUKINSA Momentum

Fineline Cube Nov 7, 2025

BeOne Medicines Ltd. (NASDAQ: ONC, HKG: 6160, SHA: 688235) released its third‑quarter 2025 financial results, reporting...

Company Drug

CStone Pharmaceuticals to Unveil CS2015 Data at 2025 ACAA​I Meeting

Fineline Cube Nov 7, 2025

China‑based CStone Pharmaceuticals (HKG: 2616) announced that the pre‑clinical results for its bispecific biologic CS2015...

Company Deals

AmacaThera Signs Exclusive Global License with Pacira BioSciences for AMT‑143, Up to $230 M Deal

Fineline Cube Nov 7, 2025

AmacaThera, the hydrogel‑technology biotech incubated by Viva BioInnovator (VBI), announced an exclusive worldwide licensing agreement...

Others

Sanofi’s Cablivi Wins China NMPA Approval – First Nanobody Drug for aTTP

Fineline Cube Nov 7, 2025

Sanofi (NASDAQ: SNY) announced that its anti‑vWF Nanobody Cablivi (caplacizumab for injection) received formal marketing...

Others

Judge Rejects Pfizer’s Attempt to Block Novo Nordisk’s $10 bn Bid for Metsera

Fineline Cube Nov 7, 2025

Delaware Court of Chancery Judge Morgan Zurn denied Pfizer’s (NYSE: PFE) request for a temporary...

Company

Amgen Reports 12% YoY Sales Growth in Q3 2025, Raises Full‑Year Revenue Guidance

Fineline Cube Nov 7, 2025

US‑based biotech giant Amgen (NASDAQ: AMGN) posted its third‑quarter 2025 results, showing total sales of...

Company

AstraZeneca Posts 11% Y/Y Revenue Rise to $43.24 bn in First Nine‑Months of 2025

Fineline Cube Nov 7, 2025

AstraZeneca (AZ, NASDAQ: AZN) released its third‑quarter and nine‑month 2025 financial results, showing total revenues...

Posts pagination

1 … 22 23 24 … 606

Recent updates

  • Betta Pharmaceuticals Partners with Westlake University on Pharma Innovation
  • Viva Biotech and CMS Forge AI-Powered Drug Development Alliance
  • Hisun and ECNU Forge AI Drug Discovery Partnership
  • NMPA Issues Priority Review Guidelines for Clinically Urgent Overseas Drugs
  • Sciclon Licenses Augtyro Promotion Rights from Zai Lab for China Market
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Betta Pharmaceuticals Partners with Westlake University on Pharma Innovation

Company Deals

Viva Biotech and CMS Forge AI-Powered Drug Development Alliance

Company Deals

Hisun and ECNU Forge AI Drug Discovery Partnership

Policy / Regulatory

NMPA Issues Priority Review Guidelines for Clinically Urgent Overseas Drugs

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.